Med. praxi. 2022;19(5):385-390

Časná kompenzace hypertenze aneb jak se nedostat tam, odkud není cesty zpět

MUDr. Peter Wohlfahrt, Ph.D.
Pracoviště preventivní kardiologie IKEM, Praha

Na 19. kongresu Medicíny pro praxi zazněla 21. 10. 2022 přednáška zaměřená na význam včasného zahájení léčby hypertenze, a to zejména u pacientů mladšího věku. MUDr. Wohlfahrt na výsledcích řady studií ukázal, že neléčená nebo nedostatečně léčená hypertenze vede k poškození cílových orgánů a že při vzniku hypertenze v mladším věku působí tento kardiovaskulární rizikový faktor řadu let a navozuje ireverzibilní orgánové změny. Mezi cílové orgány hypertenze patří i mozek, který je ohrožen atrofií a dalšími změnami spojenými s poklesem kognitivních funkcí a rozvojem demence. Pro dosažení kompenzace krevního tlaku k cílovým hodnotám, navíc do 3 měsíců, jak uvádějí doporučení, je obvykle nutná nejméně dvojkombinace antihypertenziv. Pro intenzifikaci léčby lze využít fixní trojkombinaci s výhodou časného dosažení cílových hodnot, dobré tolerance a adherence, jakou prokázal např. Triplixam®.

Published: November 29, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wohlfahrt P. Časná kompenzace hypertenze aneb jak se nedostat tam, odkud není cesty zpět. Med. praxi. 2022;19(5):385-390.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Niiranen TJ, McCabe EL, Larson MG, et al. Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham Heart Study. BMJ. 2017;357:j1949. Go to original source... Go to PubMed...
    2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-3104. Go to original source... Go to PubMed...
    3. Suvila K, McCabe EL, Lehtonen A, et al. Early Onset Hypertension Is Associated With Hypertensive End­‑Organ Damage Already by MidLife. Hypertension. 2019 Jul 1: HYPERTENSIONAHA11913069. Go to original source...
    4. Fernández­‑Friera L, Peñalvo JL, Fernández­‑Ortiz A, et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle­‑Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131(24):2104-2113. Go to original source... Go to PubMed...
    5. Schaare HL, Kharabian Masouleh S, et al. Association of peripheral blood pressure with gray matter volume in 19- to 40-year­‑old adults. Neurology. 2019;92(8):e758-e773. Go to original source... Go to PubMed...
    6. Maillard P, Mitchell GF, Himali JJ, et al. Effects of Arterial Stiffness on Brain Integrity in Young Adults From the Framingham Heart Study. Stroke. 2016;47(4):1030-1036. Go to original source... Go to PubMed...
    7. Suvila K, Lima JAC, Yano Y, et al. Early­‑but Not Late­‑Onset Hypertension Is Related to Midlife Cognitive Function. Hypertension. 2021;77(3):972-979. Go to original source... Go to PubMed...
    8. Shang X, Hill E, Zhu Z, et al. The Association of Age at Diagnosis of Hypertension With Brain Structure and Incident Dementia in the UK Biobank. Hypertension. 2021;78(5):1463-1474. Go to original source... Go to PubMed...
    9. Xu L, Yang Y, Cui D. Association between blood pressure control status, visit­‑to­‑visit blood pressure variability, and cognitive function in elderly Chinese: A nationwide study. Front Public Health. 2022;10:877192. Go to original source... Go to PubMed...
    10. Deng Z, Jiang J, Wang J, et al; Alzheimer's Disease Neuroimaging Initiative. Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia. Hypertension. 2022;79(10): 2159-2169. Go to original source... Go to PubMed...
    11. Lee CJ, Hwang J, Kang CY, et al. Protective effect of controlled blood pressure on risk of dementia in low­‑risk, grade 1 hypertension. J Hypertens. 2021;39(8):1662-1669. Go to original source... Go to PubMed...
    12. Gradman AH, Parisé H, Lefebvre P, et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61(2):309-318. Go to original source... Go to PubMed...
    13. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124-1131. Go to original source... Go to PubMed...
    14. Rahimi K, Bidel Z, Nazarzadeh M, et al. Age­‑stratified and blood­‑pressure­‑stratified effects of blood­‑pressure­‑lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant­‑level data meta­‑analysis. The Lancet. 2021;398(10305):1053-1064. Go to original source... Go to PubMed...
    15. Roush GC, Ernst ME, Kostis JB, et al. Head­‑to­‑head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041-1046. Go to original source... Go to PubMed...
    16. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin­‑converting enzyme inhibitors reduce mortality in hypertension: a meta­‑analysis of randomized clinical trials of renin­‑angiotensin­‑aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088-2097. Go to original source... Go to PubMed...
    17. Lv J, Perkovic V, Foote CV, et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012;12:CD004136. Go to original source... Go to PubMed...
    18. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin­‑converting enzyme inhibitors or angiotensin II­‑receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151(12):861-871. Go to original source...
    19. Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST­‑segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST­‑segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. Go to original source... Go to PubMed...
    20. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Go to original source... Go to PubMed...
    21. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013;33(8):553-561. Go to original source... Go to PubMed...
    22. Bangalore S, Kumar S, Messerli FH. Angiotensin­‑converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med. 2010;123(11):1016-30. Go to original source... Go to PubMed...
    23. Lévy BI, Mourad JJ. Renin Angiotensin Blockers and Cardiac Protection: From Basis to Clinical Trials. Am J Hypertens. 2022;35(4):293-302. Go to original source... Go to PubMed...
    24. Logunova N, Khomitskaya Y, Karpov Y, et al. Antihypertensive effectiveness and tolerability of perindopril/indapamide/amlodipine triple single-pill combination in the treatment of patients with arterial hypertension (TRICOLOR), J Hypertens. 2021;39:e373. Go to original source...
    25. Cicero AFG, Fogacci F, Rizzoli E, et al. Long­‑Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. J Clin Med. 2021;10(24):5921. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.